<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-EBN997X5/b334e8b1-1eed-4f60-8e25-9f32ce7a04d4/PDF"><dcterms:extent>825 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-EBN997X5/8997c611-1f21-458d-9f81-cca865b855b2/TEXT"><dcterms:extent>37 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-EBN997X5"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2024</dcterms:issued><dc:creator>Grilc, Nina Katarina</dc:creator><dc:creator>Kristl, Julijana</dc:creator><dc:creator>Zupančič, Špela</dc:creator><dc:format xml:lang="sl">številka:5</dc:format><dc:format xml:lang="sl">letnik:75</dc:format><dc:format xml:lang="sl">str. 367-374</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:221097987</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-EBN997X5</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="en">drying</dc:subject><dc:subject xml:lang="en">encapsulation</dc:subject><dc:subject xml:lang="sl">enkapsulacija</dc:subject><dc:subject xml:lang="en">formulation design</dc:subject><dc:subject xml:lang="en">live biotherapeutic products</dc:subject><dc:subject xml:lang="sl">načrtovanje formulacij</dc:subject><dc:subject xml:lang="en">probiotic testing</dc:subject><dc:subject xml:lang="en">probiotics</dc:subject><dc:subject xml:lang="sl">Probiotiki</dc:subject><dc:subject xml:lang="sl">sušenje</dc:subject><dc:subject xml:lang="sl">testiranje probiotikov</dc:subject><dc:subject xml:lang="sl">živi bioterapevtski izdelki</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Napredek in izzivi v razvoju živih bioterapevtskih izdelkov| Progress and challenges in the development of living biotherapeutic products|</dc:title><dc:description xml:lang="sl">The skin and mucous membranes are inhabited by microbiota, which play a crucial role in maintaining health, as its imbalance can lead to various diseases. Probiotics contribute to restoring microbiota balance through mechanisms such as inhibiting pathogen colonization, modulating the immune system, and strengthening the protective function of mucous membranes. This paper discusses traditional probiotics as well as next-generation probiotics designed for use in live biotherapeutic products. Their development requires appropriate strain selection, specific characterization, drying method optimization, and formulation adaptation for each strain. A quality probiotic product must contain sufficient live bacteria that retain their biological activity from incorporation into the formulation, through storage, to delivery at the target site. Despite fast scientific advances, ensuring the high survival rate of some strains remains a technological challenge addressed in the present article. Next-generation probiotics hold great promise for the prevention and treatment of some infectious and inflammatory diseases, as evidenced by intensive research in this field</dc:description><dc:description xml:lang="sl">Koža in sluznice so naseljene z mikrobioto, ki ima ključno vlogo pri ohranjanju zdravja, saj lahko njeno neravnovesje povzroči različne bolezni. Probiotiki prispevajo k ponovni vzpostavitvi mikrobiotskega ravnovesja z različnimi mehanizmi, med katerimi so preprečevanje naselitve patogenov, modulacija imunskega sistema in krepitev zaščitne funkcije sluznic. V prispevku so obravnavani tradicionalni probiotiki ter probiotiki nove generacije, namenjeni uporabi v živih bioterapevtskih izdelkih. Za izdelavo le-teh so ključni ustrezna izbira sevov, njihova specifična karakterizacija, izbira metode sušenja in prilagoditev formulacije za vsak sev posebej. Kakovosten izdelek s probiotiki mora vsebovati zadostno količino živih bakterij, ki morajo ohraniti njihovo biološko aktivnost od vgradnje v formulacijo, shranjevanja do dostave na tarčno mesto. Kljub hitremu znanstvenemu napredku pa prav visoka stopnja preživetja nekaterih sevov še vedno predstavlja tehnološki izziv, ki je opisan v pričujočem članku. Probiotiki nove generacije obetajo velik potencial pri preprečevanju in zdravljenju nekaterih infekcijskih in vnetnih bolezni, kar je razvidno iz intenzivnih raziskav na tem področju</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-EBN997X5"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-EBN997X5" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-EBN997X5/b334e8b1-1eed-4f60-8e25-9f32ce7a04d4/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-EBN997X5/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-EBN997X5" /></ore:Aggregation></rdf:RDF>